Cost-effectiveness of biomarker-directed toripalimab plus chemotherapy for previously untreated extensive-stage small-cell lung-cancer in China.

Cost-effectiveness of biomarker-directed toripalimab plus chemotherapy for previously untreated extensive-stage small-cell lung-cancer in China.

Show other versions (1)

<h4>Background</h4>With or without biomarker-directed toripalimab plus chemotherapy could bring significant clinical benefit and acceptable safety profile compared with chemotherapy as first-line treatment for patients with extensive-stage small-cell lung-cancer (ES-SCLC) were demonstrat...

Full description

Saved in:
Bibliographic Details
Main Authors: Shuo Kang, Shan Zhao, Xiaohui Wang, Zhenhua Pan
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2025-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0328730
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items